B+
Bull case
25%
Probability
Target price
$5.00
Analysis reference price unavailable
Analysis 2026-08-04 · RankAlpha Sentiment Codex
MYGN
Myriad GeneticsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$3.25
Analysis reference price unavailable
Analysis 2026-08-04 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$2.10
Analysis reference price unavailable
Analysis 2026-08-04 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-04
Recent news sentiment (30D)
-0.6
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+69.5
Score
AI commentary
Post-earnings news tone is negative, reflecting the guidance reduction and suspended EBITDA outlook. The packet does not provide a clean event-window price return or verified analyst target and estimate revisions; missing revision data is not positive evidence. Social sentiment, options skew, short interest, and employee sentiment were unavailable.
RankAlpha Sentiment Codex - 2026-08-04
Open full AI memoEvidence flagged
peer set is too generic or lacks enough direct operating comparators; small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report
Impact
tentative
Confidence
-
AI events
2026-11-02eventAscend efficiency and revenue-cycle executionHigh impact
Management activated Ascend, engaged a professional-services firm, and initiated payer and revenue-cycle actions. Timing and financial effects remain uncertain, making this an execution-dependent event rather than a firm recovery signal [#SEC-8K-2026-07-30].
2026-11-02catalystQ2 guidance reset and reimbursement pressureHigh impact
Q2 revenue was $190.7 million, down 11% year over year, with lower test volume and average revenue per test. Management cut 2026 revenue guidance to $770–$790 million, lowered gross-margin guidance to 66%–67%, and suspended adjusted EBITDA guidance amid prenatal weakness and payer friction [#SEC-8K-2026-07-30].
2027-08-04catalystPrecise MRD program expansion and MolDX coverageHigh impact
The Cancer Care Continuum showed 6% year-over-year volume growth, while Myriad launched Prolaris + AI, expanded Precise MRD into colorectal and renal cancers, and submitted Precise MRD for breast cancer coverage determination. This is a long-horizon program and regulatory-coverage catalyst, but timing and commercial impact remain uncertain [#SEC-8K-2026-07-30].
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-04 • Updated nightlySource: Internal modelMethodology